Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

Carrasco-García E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gómez-Martínez A, García-Morales P, Ferragut JA, Martínez-Lacaci I.

Exp Cell Res. 2011 Jun 10;317(10):1476-89. doi: 10.1016/j.yexcr.2011.03.015. Epub 2011 Apr 1.

PMID:
21439954
2.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.

PMID:
18696232
3.
4.

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.

Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, Schlegel J.

Int J Mol Med. 2010 Nov;26(5):713-21.

PMID:
20878094
5.

PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.

Petri MK, Brobeil A, Planz J, Bräuninger A, Gattenlöhner S, Nestler U, Stenzinger A, Paradowska A, Wimmer M.

J Neurooncol. 2015 May;123(1):15-25. doi: 10.1007/s11060-015-1763-8. Epub 2015 Apr 11.

PMID:
25862004
7.

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP.

Cancer Biol Ther. 2007 Apr;6(4):548-54.

PMID:
17457047
9.
10.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
11.

Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.

Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.

Cancer Lett. 2007 Apr 8;248(1):32-40. Epub 2006 Jul 11.

PMID:
16837130
12.

Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.

Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.

Mol Cancer Res. 2007 Apr;5(4):393-401.

13.

Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta.

Yamaguchi K, Richardson MD, Bigner DD, Kwatra MM.

Cancer Chemother Pharmacol. 2005 Dec;56(6):585-93. Epub 2005 Jul 13.

PMID:
16012865
14.

Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.

Li M, Wang J, Ng SS, Chan CY, He ML, Yu F, Lai L, Shi C, Chen Y, Yew DT, Kung HF, Lin MC.

Cancer. 2009 Nov 1;115(21):4959-72. doi: 10.1002/cncr.24550.

15.

Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.

Zhang YG, Du Q, Fang WG, Jin ML, Tian XX.

Int J Oncol. 2008 Sep;33(3):595-602.

PMID:
18695891
16.

EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.

Krohn V, Wiegand S, Werner JA, Mandic R.

Anticancer Res. 2011 Jan;31(1):59-65.

PMID:
21273581
17.

Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.

Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Kanadaswam C, Lee MT.

Anticancer Res. 2002 May-Jun;22(3):1615-27.

PMID:
12168845
18.

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.

Cancer Res. 2006 Jan 1;66(1):404-11.

19.

Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.

Kim SH, Song YC, Kim SH, Jo H, Song YS.

Ann N Y Acad Sci. 2009 Aug;1171:642-8. doi: 10.1111/j.1749-6632.2009.04893.x.

PMID:
19723115
20.

Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.

Liu FJ, Gui SB, Li CZ, Sun ZL, Zhang YZ.

Chin Med J (Engl). 2008 Sep 5;121(17):1702-6.

PMID:
19024103

Supplemental Content

Support Center